Endoscopic Ultrasound-Guided Ethanol Ablation for Aldosterone-Producing Adenoma (CREATE)
Endoscopic Ultrasound-Guided Ethanol Ablation of Aldosterone-Producing Adenomas
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Shumin Yang, MD, PhD
- Telefonnummer: +86-023-89011552
- E-post: ysm@hospital.cqmu.edu.cn
Studer Kontakt Backup
- Navn: Liang Deng, MD, PhD
- Telefonnummer: +86-023-89011510
- E-post: dengliang@hospital.cqmu.edu.cn
Studiesteder
-
-
Choongqing
-
Chongqing, Choongqing, Kina, 400016
- The First Affiliated Hospital of Chongqing Medical University
-
Ta kontakt med:
- Shumin Yang, MD, PhD
- Telefonnummer: +86 023-89011552
- E-post: ysm@hospital.cqmu.edu.cn
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Diagnosis of left-sided aldosterone-producing adrenal adenoma.
- Unwillingness to undergo adrenalectomy or presence of contraindications to surgery.
- Ability and willingness to provide written informed consent.
Exclusion Criteria:
- History of alcohol allergy.
- Inability to discontinue beta-blockers.
- Inability to discontinue anticoagulants, antiplatelet agents, or glucocorticoids.
- Platelet count <50 × 10^9/L or uncorrectable coagulation dysfunction.
- Imaging findings suggestive of adrenal cyst, adrenal hematoma, or myelolipoma.
- Presence of other active malignancies.
- Pregnancy or breastfeeding; alcohol abuse; drug abuse; or mental disorder that may interfere with study participation.
- Severe comorbid conditions, including any of the following: New York Heart Association (NYHA) class III-IV heart failure or hospitalization for worsening chronic heart failure within the previous 3 months; stroke or acute coronary syndrome within the previous 3 months; severe anemia (hemoglobin <60 g/L); severe hepatic disease (alanine aminotransferase ≥3 × the upper limit of normal); severe renal disease requiring dialysis or estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²; systemic inflammatory response syndrome (SIRS); poorly controlled diabetes mellitus (fasting blood glucose ≥13.3 mmol/L); severe obesity (body mass index ≥35 kg/m²); untreated aneurysm; or any other severe medical condition that may interfere with treatment or study follow-up.
- Poor compliance or any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Endoscopic Ultrasound-Guided Ethanol Ablation
Participants with left-sided unilateral aldosterone-producing adenoma undergo endoscopic ultrasound-guided ethanol ablation under real-time endoscopic ultrasound guidance.
|
Participants with left-sided aldosterone-producing adenoma undergo endoscopic ultrasound-guided ethanol ablation under real-time endoscopic ultrasound guidance.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Procedure-related major adverse events
Tidsramme: Within 24-48 hours after endoscopic ultrasound-guided ethanol ablation
|
Assessment of predefined procedure-related major adverse events occurring within 24-48 hours after endoscopic ultrasound-guided ethanol ablation, including imaging-confirmed major bleeding, gastrointestinal perforation, major organ infarction, and hypertensive urgency or emergency (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥120 mmHg).
|
Within 24-48 hours after endoscopic ultrasound-guided ethanol ablation
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete tumor ablation on imaging
Tidsramme: 6 months after endoscopic ultrasound-guided ethanol ablation
|
Complete radiologic ablation will be assessed by PET/CT at 6 months after endoscopic ultrasound-guided ethanol ablation.
Complete ablation is defined as no abnormal radiotracer uptake in the treated adrenal lesion.
|
6 months after endoscopic ultrasound-guided ethanol ablation
|
|
Complete biochemical remission rate
Tidsramme: 6 months after endoscopic ultrasound-guided ethanol ablation
|
The proportion of participants with complete biochemical remission at 6 months after endoscopic ultrasound-guided ethanol ablation will be assessed according to the PASO consensus criteria.
Complete biochemical remission is defined as normalization of serum potassium and aldosterone-to-renin ratio, or normalization of serum potassium with suppressed aldosterone secretion on confirmatory testing, defined as post-SSIT aldosterone <80 pg/mL or post-CCT aldosterone <110 pg/mL.
|
6 months after endoscopic ultrasound-guided ethanol ablation
|
|
Complete clinical remission rate
Tidsramme: 6 months after endoscopic ultrasound-guided ethanol ablation
|
The proportion of participants with complete clinical remission at 6 months after endoscopic ultrasound-guided ethanol ablation will be assessed according to the PASO consensus criteria.
Complete clinical remission is defined as normal blood pressure without any antihypertensive medication.
|
6 months after endoscopic ultrasound-guided ethanol ablation
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Shumin Yang, MD, PhD, First Affiliated Hospital of Chongqing Medical University
- Hovedetterforsker: Liang Deng, MD, PhD, First Affiliated Hospital of Chongqing Medical University
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 2026-0558-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .